The FDA has approved Phesgo™ (pertuzumab, trastuzumab, hyaluronidase-zzxf; Genentech), in combination with chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.
Polygenic risk scores incorporating scores of SNPs associated with breast cancer risk have been used as breast cancer risk-stratification tools.
Race and ethnicity were key data points collected from the cohort and tracked with outcomes.
The detection of acquired ESR1 mutations in patients with hormone receptor (HR) positive metastatic breast cancer predicted poor clinical benefit from exemestane.
The incidence of breast cancer for postmenopausal women included in the NIH-AARP study was evaluated with respect to level of outdoor light at night.
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Patients with early-stage breast cancer who undergo mastectomy with or without reconstruction are at risk of prolonged opioid use.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Larger surgical margin widths were associated with a lower rate of invasive breast cancer in certain individuals.
Controversy exists regarding whether to offer early locoregional treatment in addition to palliative therapy to patients with de novo MBC and an intact primary tumor.
Nearly half of the patients with advanced HER2-positive breast cancer enrolled in the randomized, phase II HER2CLIMB trial had disease that had metastasized to the brain.
PI3KCA is mutated in approximately 40% of patients with HR-positive, HER2-negative advanced breast cancer, and is associated with treatment resistance and poor outcomes.
Researchers found that PET responders exhibited least a 40% reduction in SUVmax of 18F-FDG PET/CT compared with baseline following initial neoadjuvant therapy.
Researchers sought to compare neoadjuvant chemotherapy with an epirubicin-based regimen to a non-anthracycline-containing regimen in HER2-positive breast cancer.
A study compared the risk of ipsilateral invasive breast cancer in patients with DCIS undergoing breast-conserving therapy with surveillance alone.
There was a trend toward improved efficacy with PD-L1 enrichment.
Margin size was not associated with locoregional recurrence for patients with breast cancer who underwent breast-conserving surgery and neoadjuvant chemotherapy.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
A review of prior screening mammograms of patients diagnosed with breast cancer allowed for the retrospective identification of previously missed tumors.
High risks for breast cancer associated with mutations in BRCA1, BRCA2, PALB2.